knee replacement
Conditions
Interventions
control group:Sufentanil 1.5ug/kg+ Troisetron 6mg was diluted to 110ml with normal saline, and the load dose was not set, the controlled analgesic dose was 0.5mL/time by continuous infusion of 2mL/h,
dexmedetomidine group 1:Sufentanil 1.5ug/kg+ Dexmedetomidine 0.0125ug/kg/h+ Toxisetron 6mg were diluted to 110ml with normal saline without load dose, the controlled analgesic dose was 0.5mL/time by c
dexmedetomidine group 2:Sufentanil 1.5ug/kg+ Dexmedetomidine 0.025ug/kg/h+ Toxisetron 6mg were diluted to 110ml with normal saline without load dose, the controlled analgesic dose was 0.5mL/time by co
dexmedetomidine group 3:Sufentanil 1.5ug/kg+ Dexmedetomidine 0.05ug/kg/h+ Torisetron 6mg were diluted to 110ml with normal saline without load dose, the controlled analgesic dose was 0.5mL/time by con
Sponsors
Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Age
60 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged from 60 to 75 years; 2. ASA grade I-III; 3. Patients who plan to undergo unilateral knee arthroplasty and require postoperative analgesic pump; 4. BMI 18.5-27kg/m2.
Exclusion criteria
Exclusion criteria: 1. Impaired hearing and language communication, unable to communicate effectively with doctors; 2. Patients with allergies to any drug in the study; 3. Other operations within 1 year or 3 months of contralateral knee replacement; 4. Patients with sinus bradycardia (heart rate less than 50 beats/min) or sinus node lesions, second or third degree atrioventricular block, or equipped with pacemaker before surgery; 5. Patients with severe heart, liver and kidney diseases; 6. Patients with obstructive sleep apnea or moderate or above snoring; 7. Patients with mental illness that will affect postoperative rehabilitation and follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PSQI score; | — |
Countries
China
Contacts
Public ContactCheng Wei
Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed